{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T06:08:53Z","timestamp":1791094133472,"version":"4.1.0"},"reference-count":48,"publisher":"American Association for Cancer Research (AACR)","issue":"23","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Murine studies have shown that immunologic targeting of the tumor vasculature, a key element of the tumor stroma, can lead to protective immunity in the absence of significant pathology. In the current study, we expand the scope of stroma-targeted immunotherapy to antigens expressed in tumor-associated fibroblasts, the predominant component of the stroma in most types of cancer. Mice were immunized against fibroblast activation protein (FAP), a product up-regulated in tumor-associated fibroblasts, using dendritic cells transfected with FAP mRNA. Using melanoma, carcinoma, and lymphoma models, we show that tumor growth was inhibited in tumor-bearing mice vaccinated against FAP and that the magnitude of the antitumor response was comparable to that of vaccination against tumor cell\u2013expressed antigens. Both s.c. implanted tumors and lung metastases were susceptible to anti-FAP immunotherapy. The antitumor response could be further enhanced by augmenting the CD4+ T-cell arm of the anti-FAP immune response, achieved by using a lysosomal targeting sequence to redirect the translated FAP product into the class II presentation pathway, or by covaccination against FAP and a tumor cell\u2013expressed antigen, tyrosinase-related protein 2. No morbidity or mortality was associated with anti-FAP vaccination except for a small delay in wound healing. The study suggests that FAP, a product which is preferentially expressed in tumor-associated fibroblasts, could function as a tumor rejection antigen in a broad range of cancers.<\/jats:p>","DOI":"10.1158\/0008-5472.can-05-2805","type":"journal-article","created":{"date-parts":[[2005,12,1]],"date-time":"2005-12-01T20:48:14Z","timestamp":1133470094000},"page":"11156-11163","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":145,"title":["Tumor Immunotherapy Targeting Fibroblast Activation Protein, a Product Expressed in Tumor-Associated Fibroblasts"],"prefix":"10.1158","volume":"65","author":[{"given":"Jaewoo","family":"Lee","sequence":"first","affiliation":[{"name":"Center for Translational Research, Department of Surgery, Duke University Medical Center, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Fassnacht","sequence":"additional","affiliation":[{"name":"Center for Translational Research, Department of Surgery, Duke University Medical Center, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smita","family":"Nair","sequence":"additional","affiliation":[{"name":"Center for Translational Research, Department of Surgery, Duke University Medical Center, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Boczkowski","sequence":"additional","affiliation":[{"name":"Center for Translational Research, Department of Surgery, Duke University Medical Center, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eli","family":"Gilboa","sequence":"additional","affiliation":[{"name":"Center for Translational Research, Department of Surgery, Duke University Medical Center, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2005,12,1]]},"reference":[{"key":"2022061621072474300_B1","doi-asserted-by":"crossref","unstructured":"Garrido F, Algarra I. MHC antigens and tumor escape from immune surveillance. Adv Cancer Res\u20082001; 83: 117\u201358.","DOI":"10.1016\/S0065-230X(01)83005-0"},{"key":"2022061621072474300_B2","doi-asserted-by":"crossref","unstructured":"Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T cell recognition: molecular mechanisms and functional significance. Adv Immunol\u20082000; 74: 181\u2013273.","DOI":"10.1016\/S0065-2776(08)60911-6"},{"key":"2022061621072474300_B3","doi-asserted-by":"crossref","unstructured":"Gilboa E. The promise of cancer vaccines. Nat Rev Cancer\u20082004; 4: 401\u201311.","DOI":"10.1038\/nrc1359"},{"key":"2022061621072474300_B4","doi-asserted-by":"crossref","unstructured":"Wei YQ, Wang QR, Zhao X, et al. Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Nat Med\u20082000; 6: 1160\u20136.","DOI":"10.1038\/80506"},{"key":"2022061621072474300_B5","doi-asserted-by":"crossref","unstructured":"Niethammer AG, Xiang R, Becker JC, et al. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med\u20082002; 8: 1369\u201375.","DOI":"10.1038\/nm1202-794"},{"key":"2022061621072474300_B6","doi-asserted-by":"crossref","unstructured":"Li Y, Wang MN, Li H, et al. Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis. J Exp Med\u20082002; 195: 1575\u201384.","DOI":"10.1084\/jem.20020072"},{"key":"2022061621072474300_B7","doi-asserted-by":"crossref","unstructured":"Nair S, Boczkowski D, Moeller B, Dewhirst M, Vieweg J, Gilboa E. Synergy between tumor immunotherapy and antiangiogenic therapy. Blood\u20082003; 102: 964\u201371.","DOI":"10.1182\/blood-2002-12-3738"},{"key":"2022061621072474300_B8","doi-asserted-by":"crossref","unstructured":"Mueller MM, Fusenig NE. Friends or foes\u2014bipolar effects of the tumour stroma in cancer. Nat Rev Cancer\u20082004; 4: 839\u201349.","DOI":"10.1038\/nrc1477"},{"key":"2022061621072474300_B9","doi-asserted-by":"crossref","unstructured":"Elenbaas B, Weinberg RA. Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. Exp Cell Res\u20082001; 264: 169\u201384.","DOI":"10.1006\/excr.2000.5133"},{"key":"2022061621072474300_B10","doi-asserted-by":"crossref","unstructured":"Tuxhorn JA, Ayala GE, Rowley DR. Reactive stroma in prostate cancer progression. J Urol\u20082001; 166: 2472\u201383.","DOI":"10.1016\/S0022-5347(05)65620-0"},{"key":"2022061621072474300_B11","doi-asserted-by":"crossref","unstructured":"Li G, Satyamoorthy K, Meier F, Berking C, Bogenrieder T, Herlyn M. Function and regulation of melanoma-stromal fibroblast interactions: when seeds meet soil. Oncogene\u20082003; 22: 3162\u201371.","DOI":"10.1038\/sj.onc.1206455"},{"key":"2022061621072474300_B12","doi-asserted-by":"crossref","unstructured":"Tlsty TD, Hein PW. Know thy neighbor: stromal cells can contribute oncogenic signals. Curr Opin Genet Dev\u20082001; 11: 54\u20139.","DOI":"10.1016\/S0959-437X(00)00156-8"},{"key":"2022061621072474300_B13","doi-asserted-by":"crossref","unstructured":"Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature\u20082004; 432: 332\u20137.","DOI":"10.1038\/nature03096"},{"key":"2022061621072474300_B14","doi-asserted-by":"crossref","unstructured":"Nakagawa H, Liyanarachchi S, Davuluri RV, et al. Role of cancer-associated stromal fibroblasts in metastatic colon cancer to the liver and their expression profiles. Oncogene\u20082004; 23: 7366\u201377.","DOI":"10.1038\/sj.onc.1208013"},{"key":"2022061621072474300_B15","doi-asserted-by":"crossref","unstructured":"Kreuwel HT, Sherman LA. The T-cell repertoire available for recognition of self-antigens. Curr Opin Immunol\u20082001; 13: 639\u201343.","DOI":"10.1016\/S0952-7915(01)00272-2"},{"key":"2022061621072474300_B16","doi-asserted-by":"crossref","unstructured":"Fassnacht M, Lee J, Milazzo C, et al. Induction of CD4+ and CD8+ T-cell responses to the human stromal antigen, fibroblast activation protein: Implication for cancer immunotherapy. Clin Cancer Res\u20082005; 11: 5566\u201371.","DOI":"10.1158\/1078-0432.CCR-05-0699"},{"key":"2022061621072474300_B17","doi-asserted-by":"crossref","unstructured":"Garin-Chesa P, Old LJ, Rettig WJ. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci U S A\u20081990; 87: 7235\u20139.","DOI":"10.1073\/pnas.87.18.7235"},{"key":"2022061621072474300_B18","doi-asserted-by":"crossref","unstructured":"Park JE, Lenter MC, Zimmermann RN, Garin-Chesa P, Old LJ, Rettig WJ. Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts. J Biol Chem\u20081999; 274: 36505\u201312.","DOI":"10.1074\/jbc.274.51.36505"},{"key":"2022061621072474300_B19","doi-asserted-by":"crossref","unstructured":"Rettig WJ, Garin-Chesa P, Beresford HR, Oettgen HF, Melamed MR, Old LJ. Cell-surface glycoproteins of human sarcomas: differential expression in normal and malignant tissues and cultured cells. Proc Natl Acad Sci U S A\u20081988; 85: 3110\u20134.","DOI":"10.1073\/pnas.85.9.3110"},{"key":"2022061621072474300_B20","doi-asserted-by":"crossref","unstructured":"Huber MA, Kraut N, Park JE, et al. Fibroblast activation protein: differential expression and serine protease activity in reactive stromal fibroblasts of melanocytic skin tumors. J Invest Dermatol\u20082003; 120: 182\u20138.","DOI":"10.1046\/j.1523-1747.2003.12035.x"},{"key":"2022061621072474300_B21","doi-asserted-by":"crossref","unstructured":"Levy MT, McCaughan GW, Abbott CA, et al. Fibroblast activation protein: a cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodelling interface in human cirrhosis. Hepatology\u20081999; 29: 1768\u201378.","DOI":"10.1002\/hep.510290631"},{"key":"2022061621072474300_B22","unstructured":"Rettig WJ, Garin-Chesa P, Healey JH, et al. Regulation and heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectodermal origin. Cancer Res\u20081993; 53: 3327\u201335."},{"key":"2022061621072474300_B23","doi-asserted-by":"crossref","unstructured":"Scanlan MJ, Raj BK, Calvo B, et al. Molecular cloning of fibroblast activation protein \u03b1, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. Proc Natl Acad Sci U S A\u20081994; 91: 5657\u201361.","DOI":"10.1073\/pnas.91.12.5657"},{"key":"2022061621072474300_B24","doi-asserted-by":"crossref","unstructured":"Niedermeyer J, Scanlan MJ, Garin-Chesa P, et al. Mouse fibroblast activation protein: molecular cloning, alternative splicing and expression in the reactive stroma of epithelial cancers. Int J Cancer\u20081997; 71: 383\u20139.","DOI":"10.1002\/(SICI)1097-0215(19970502)71:3<383::AID-IJC14>3.0.CO;2-H"},{"key":"2022061621072474300_B25","doi-asserted-by":"crossref","unstructured":"Goldstein LA, Ghersi G, Pineiro-Sanchez ML, et al. Molecular cloning of seprase: a serine integral membrane protease from human melanoma. Biochim Biophys Acta\u20081997; 1361: 11\u20139.","DOI":"10.1016\/S0925-4439(97)00032-X"},{"key":"2022061621072474300_B26","unstructured":"Porgador A, Tzehoval E, Vadai E, Feldman M, Eisenbach L. Combined vaccination with major histocompatibility class I and interleukin 2 gene-transduced melanoma cells synergizes the cure of postsurgical established lung metastases. Cancer Res\u20081995; 55: 4941\u20139."},{"key":"2022061621072474300_B27","unstructured":"Miller FR, Miller BE, Heppner GH. Characterization of metastatic heterogeneity among subpopulations of a single mouse mammary tumor: heterogeneity in phenotypic stability. Invasion Metastasis\u20081983; 3: 22\u201331."},{"key":"2022061621072474300_B28","doi-asserted-by":"crossref","unstructured":"Gorer PA. Studies in antibody response of mice to tumour inoculation. Br J Cancer\u20081950; 4: 372\u20139.","DOI":"10.1038\/bjc.1950.36"},{"key":"2022061621072474300_B29","doi-asserted-by":"crossref","unstructured":"Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature\u20082001; 411: 375\u20139.","DOI":"10.1038\/35077241"},{"key":"2022061621072474300_B30","doi-asserted-by":"crossref","unstructured":"Zhao Y, Boczkowski D, Nair SK, Gilboa E. Inhibition of invariant chain expression in dendritic cells presenting endogenous antigens stimulates CD4+ T-cell responses and tumor immunity. Blood\u20082003; 102: 4137\u201342.","DOI":"10.1182\/blood-2003-06-1867"},{"key":"2022061621072474300_B31","doi-asserted-by":"crossref","unstructured":"Rossiter H, Barresi C, Pammer J, et al. Loss of vascular endothelial growth factor a activity in murine epidermal keratinocytes delays wound healing and inhibits tumor formation. Cancer Res\u20082004; 64: 3508\u201316.","DOI":"10.1158\/0008-5472.CAN-03-2581"},{"key":"2022061621072474300_B32","unstructured":"Schreurs MW, Eggert AA, de Boer AJ, et al. Dendritic cells break tolerance and induce protective immunity against a melanocyte differentiation antigen in an autologous melanoma model. Cancer Res\u20082000; 60: 6995\u20137001."},{"key":"2022061621072474300_B33","doi-asserted-by":"crossref","unstructured":"Toes RE, Ossendorp F, Offringa R, Melief CJ. CD4 T cells and their role in antitumor immune responses. J Exp Med\u20081999; 189: 753\u20136.","DOI":"10.1084\/jem.189.5.753"},{"key":"2022061621072474300_B34","doi-asserted-by":"crossref","unstructured":"Wang RF. The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity. Trends Immunol\u20082001; 22: 269\u201376.","DOI":"10.1016\/S1471-4906(01)01896-8"},{"key":"2022061621072474300_B35","unstructured":"Lin KY, Guarnieri FG, Staveley-O'Carroll KF, et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res\u20081996; 56: 21\u20136."},{"key":"2022061621072474300_B36","doi-asserted-by":"crossref","unstructured":"Wu TC, Guarnieri FG, Staveley-O'Carroll KF, et al. Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc Natl Acad Sci U S A\u20081995; 92: 11671\u20135.","DOI":"10.1073\/pnas.92.25.11671"},{"key":"2022061621072474300_B37","doi-asserted-by":"crossref","unstructured":"Nair SK, Boczkowski D, Morse M, Cumming RI, Lyerly HK, Gilboa E. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat Biotechnol\u20081998; 16: 364\u20139.","DOI":"10.1038\/nbt0498-364"},{"key":"2022061621072474300_B38","unstructured":"Su Z, Vieweg J, Weizer AZ, et al. Enhanced induction of telomerase-specific CD4(+) T cells using dendritic cells transfected with RNA encoding a chimeric gene product. Cancer Res\u20082002; 62: 5041\u20138."},{"key":"2022061621072474300_B39","doi-asserted-by":"crossref","unstructured":"Bissell MJ, Radisky D. Putting tumours in context. Nat Rev Cancer\u20082001; 1: 46\u201354.","DOI":"10.1038\/35094059"},{"key":"2022061621072474300_B40","doi-asserted-by":"crossref","unstructured":"Cherrington JM, Strawn LM, Shawver LK. New paradigms for the treatment of cancer: the role of anti-angiogenesis agents. Adv Cancer Res\u20082000; 79: 1\u201338.","DOI":"10.1016\/S0065-230X(00)79001-4"},{"key":"2022061621072474300_B41","doi-asserted-by":"crossref","unstructured":"Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science\u20082002; 295: 2387\u201392.","DOI":"10.1126\/science.1067100"},{"key":"2022061621072474300_B42","doi-asserted-by":"crossref","unstructured":"Kerbel RS. A cancer therapy resistant to resistance. Nature\u20081997; 390: 335\u20136.","DOI":"10.1038\/36978"},{"key":"2022061621072474300_B43","doi-asserted-by":"crossref","unstructured":"Kerbel RS, Yu J, Tran J, et al. Possible mechanisms of acquired resistance to antiangiogenic drugs: implications for the use of combination therapy approaches. Cancer Metastasis Rev\u20082001; 20: 79\u201386.","DOI":"10.1023\/A:1013172910858"},{"key":"2022061621072474300_B44","doi-asserted-by":"crossref","unstructured":"Morimoto C, Torimoto Y, Levinson G, et al. 1 F7, a novel cell surface molecule, involved in helper function of CD4 cells. J Immunol\u20081989; 143: 3430\u20139.","DOI":"10.4049\/jimmunol.143.11.3430"},{"key":"2022061621072474300_B45","doi-asserted-by":"crossref","unstructured":"Gilboa E. The makings of a tumor rejection antigen. Immunity\u20081999; 11: 263\u201370.","DOI":"10.1016\/S1074-7613(00)80101-6"},{"key":"2022061621072474300_B46","doi-asserted-by":"crossref","unstructured":"Schoenberger SP, Sercarz EE. Harnessing self-reactivity in cancer immunotherapy. Semin Immunol\u20081996; 8: 303\u20139.","DOI":"10.1006\/smim.1996.0039"},{"key":"2022061621072474300_B47","doi-asserted-by":"crossref","unstructured":"Sherman LA, Theobald M, Morgan D, et al. Strategies for tumor elimination by cytotoxic T lymphocytes. Crit Rev Immunol\u20081998; 18: 47\u201354.","DOI":"10.1615\/CritRevImmunol.v18.i1-2.60"},{"key":"2022061621072474300_B48","doi-asserted-by":"crossref","unstructured":"Pardoll DM. Inducing autoimmune disease to treat cancer. Proc Natl Acad Sci U S A\u20081999; 96: 5340\u20132.","DOI":"10.1073\/pnas.96.10.5340"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/65\/23\/11156\/2538472\/11156-11163.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/65\/23\/11156\/2538472\/11156-11163.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T18:10:45Z","timestamp":1683310245000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/65\/23\/11156\/518760\/Tumor-Immunotherapy-Targeting-Fibroblast"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12,1]]},"references-count":48,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2005,12,1]]},"published-print":{"date-parts":[[2005,12,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-05-2805","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,12,1]]}}}